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Introduction
 Thyroid carcinoma is the most common endocrine 
malignancy around the globe and papillary cancer (80%) 
followed by follicular (10%) carcinoma are the vast 
majority and collectively termed as well differentiated 
thyroid cancers (WDTC). Over the last few decades, there 
has been an increased incidence of WDTC (primarily 
papillary carcinoma) with a significant rise from 3.6 per 
100,000 in 1973 to 8.7 per 100,000 in 2002 in United 
States (US), a 2.4-fold increase (p<0.001 for trend) with 
a crescendo pattern (Davies and Welch, 2002). Similar 
increases have also been reported in Europe (Elisei et al., 
2010). Importantly most of these tumors were diagnosed 
at a smaller size (49% tumors were ≤1cm and 87% were 
≤2cm) and 58% of patients were aged <50 years (median 
age=46 years) (Edwards et al., 2002). The sentinel reason 
for this increase incidence of low risk cases is frequent 
detection on ultrasound and subsequent fine needle 
aspiration cytology (FNAC) of small thyroid nodules. 
Low risk WDTC with reported 10-year mortality rate of 
1.7% for papillary and 3.4% for combined papillary and 
follicular studies (Sawka et al., 2004), has been a major 
domain of therapeutic controversies. These controversies 
have been focused upon the extent of surgery, option 
of using and optimal dose of radioactive iodine-131 
(RAI) after surgery (adjuvant therapy), appropriate 
use of thyroxin suppression therapy and role of human 
recombinant thyrotropin (rhTSH). In this review the term 
ablation means use of RAI to completely destroy residual 
macroscopically normal thyroid tissue after gross surgical 
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Abstract
 Well differentiated thyroid cancers (WDTC), including papillary (80%) and follicular (10%) types, are the 
most common endocrine cancers globally. Over the last few decades most the diagnosed cases have fallen into 
low risk categories. Radioactive iodine-131 (RAI) has an established role in reducing recurrence and improving 
the survival in high risk patients. In patients with primary tumor size <1 cm, RAI is not recommended by many 
thyroid societies. However, low risk WDTC has been an arena of major controversies, most importantly the 
role and dose of adjuvant RAI for remnant ablation to minimize chances of recurrence and improving survival. 
This review is an attempt to update readers about the previous and existing practice based on results of non-
randomized trials and evolving trends fueled by recently published randomized studies. 
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resection of cancer. This review will be focusing upon: i) 
whether RAI should be used or not for ablation in low risk 
group? ii) If so, than what should be the dose of adjuvant 
RAI? 
Radioiodine-131 (RAI)
 Historical Background, it was Seidlin et al. (1948) 
who published their experience of RAI for treating 
pulmonary metastasis in a patient with thyroid cancer 
and in subsequent 10-12 years it was evident that RAI 
increased survival of patients with metastatic thyroid 
carcinoma. In 1970’s concept of using RAI for ablation 
got popularity and Mazzaferri and Young (1981) published 
10 years follow-up data of 576 patients revealing efficacy 
of RAI in reducing mortality and recurrence. However, 
Hay et al. (2002) presented data of 2444 patients treated 
during 1940-1999 showing no significant impact of RAI 
upon mortality and tumor recurrence in low risk thyroid 
cancer patients. Despite of these conflicting findings from 
these retrospective studies, during this period in US, 
approximately 38% of patients with WDTC are reported 
to have received RAI ablation or therapy (Edwards et al., 
2002). Similarly a survey conducted by American Thyroid 
Association published in 1996, 61% of respondents 
recommended RAI ablation for a hypothetical low-risk 
papillary cancer case (Solomon et al., 1996).
 Biophysical Properties of RAI: It’s a reactor produced 
isotope having a physical half-life of 8.02 days and 
emits beta particles with a maximal energy of 0.6 MeV 
(about 2mm tissue penetration and 90% of total absorbed 
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dose) and gamma rays of 364 and 674 KeV (10% of 
total absorbed dose) which are primarily responsible for 
radiation exposure to caregivers and public. 
 RAI is taken up and concentrated in thyroid follicular 
cells via sodium-iodide transporter (membrane transporter 
protein, NIS) which is also found in several other tissues 
that concentrate iodine such as the salivary and lacrimal 
glands, nasal mucosa, stomach, thymus, lactating breast 
and placenta (Shen et al., 1996). WDTC have thyroid 
stimulating hormone (TSH) receptors and do produce 
thyroglobulin (Tg). A serum TSH level of 25-30mU/L 
is necessary to stimulate adequate RAI uptake by the 
residual normal follicular and tumor cells (Carballo and 
Quiros, 2012). However, compared with normal thyroid 
tissue, thyroid cancer tissue has low expression of NIS 
(rather undetectable in one third cases), reduced iodine 
organification and shorter effective half-life of RAI. 
However, the cancer cells do respond to TSH stimulation, 
even in the absence of clinically evident RAI uptake 
(Robbins and Schulmberger, 2005). Successful ablation 
is characterized by an undetectable stimulated Tg level 
(<2ng/ml) with negative antithyroid antibodies, negative 
whole body iodine scan or <0.5% tracer uptake over 
thyroid bed and a negative neck ultrasound.
Controversies in use of RAI for Remnant 
Ablation in Low Risk WDTC 
 In last few decades, >80% of WDTC are <2cm and 
in these low risk patients, a low recurrence without RAI 
after total thyroidectomy (4%) (Vaisman et al., 2011) 
and 10 year cause specific mortality of 1.7% has been 
documented. Furthermore, in recent years, there has been 
an increasing concern over RAI induced second primary 
malignancy (SPM) and its other side effects which have 
fueled ongoing debate about the role of RAI ablation and 
ablation dose in low risk patients with WDTC.
 In patients with follicular cell origin thyroid cancers 
(i.e. WDTC) who had total or near thyroidectomy, RAI is 
used to destroy macroscopically residual normal thyroid 
tissue (adjuvant ablation). The theoretical goals of adjuvant 
ablation are: i) to destroy any residual microscopic disease; 
ii) to enhance sensitivity of diagnostic whole body iodine 
scan (WBIS) and specificity of serum Tg which facilitate 
follow up and early detection of recurrence or metastatic 
disease; and iii) use of post ablative WBIS which is more 
sensitive than diagnostic WBIS for detection of nodal 
or distant functioning metastases (Carballo and Quiros, 
2012). 
Remnant Ablation or Not in Low Risk 
WDTC?
There is large number of proponents of RAI ablation 
in high and intermediate risk patients with a tumor >4cm, 
gross extrathyroidal extension, aggressive histology, and 
presence of distant metastases due to its established role 
in reducing the recurrence and improving the survival 
(Mazaferri and Young, 1981; Yamashita et al., 1997; 
Pacini et al., 1994; AACE, 2001; Brierley et al., 2005). 
Similarly, there seems to be a consensus among major 
stake holders regarding not using adjuvant RAI ablation 
for tumor <1cm including multifocal microcarcinoma 
without any high risk features (British Thyroid Association 
Guidelines, 2007; Cooper et al., 2009). For patients in 
between these extremes, evidence for RAI effectiveness 
is largely inconclusive, conflicting or lacking (Maenpaa et 
al., 2008). However, despite the lack of robust evidence, 
use of RAI has been increasing in low risk patients which 
raise concern that these patients are being over-treated 
(Haymart et al., 2011) with an undeniable chances of 
radiation induced SPM and other long term side effects 
(Iyer et al., 2011). The absolute risk for radioiodine-
induced cancers has not been well established, but the 
risk of any SPM after initial diagnosis of thyroid cancer 
is increased approximately 30% over that of the general 
population (Sandeep et al., 2006) and the risk appears 
to increase with increasing cumulative administered 
activity (Rubino et al., 2003). Radioiodine treatment may 
be associated with nausea, taste disturbance, transient 
hypospermia and amenorrhea; permanent gonadal damage 
has been observed with cumulative activities exceeding 
>500 mCi (18500 MBq) (Maenpaa et al., 2008).
A land mark retrospective study (576 patients) 
published by Mazzaferri and Young (1981) revealed 
lowest recurrence and mortality in patients who had near 
total thyroidectomy, RAI and thyroxin therapy while 
in tumor <1.5cm, RAI did not have significant impact. 
Mazaferri and Kloos (2001) published findings based on 
1510 patients (without distant metastases at the time of 
initial therapy) who were followed-up for 40 years, that 
RAI ablation to be an independent variable that reduced 
locoregional recurrence, distant metastases, and cancer 
death. However, these findings were not confirmed in 
an analysis performed in an identical fashion on a series 
of 1542 patients treated at Mayo clinic (Grebe and Hay, 
1997). In 2002, Mayo Clinic again presented data of 2444 
patients and claimed that RAI ablation had not improved 
already excellent cause specific mortality (CSM) and 
tumor recurrence (TR) in low risk patients managed by 
near total thyroidectomy and conservative nodal excision 
(Hey et al., 2002). Schlumberger and Hay argued that 
extent and completeness of thyroidectomy (adequacy of 
surgery) was the seminal reason of different results in 
these studies (Wartofsky et al., 1998). This notion was 
further supported by a multicenter Canadian trial upon 
1578 patients revealed low TR and CSM in patients with 
residual microscopic disease treated postoperatively with 
either RAI ablation or external beam radiotherapy or both 
together than those treated with thyroid hormone alone. 
While in patients without obvious residual disease, RAI 
ablation did not significantly improve survival (Simpson et 
al., 1998). However, National Thyroid Cancer Treatment 
Cooperative Study Group (NTCTCSG) published data 
of 4,767 patients with >5 year follow-up in 2010 with a 
revised conclusion of no significant impact of RAI ablation 
upon survival of low risk patients (Jonklaas et al., 2010). 
NTCTCSG also ruled out its previous findings published 
in 2006 showing adverse effect of RAI on over-all survival 
in low risk patient (Schvartz et al., 2012). Schvartz et al. 
(2012) published a retrospective study accrued 1298 low 
risk patients with a median follow up of 10 years which 
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failed to prove any survival benefit of RAI after surgery 
in low risk group with WDTC. So the controversy is 
still on about the use of RAI in low risk patients with 
WDTC as available data are fueled by retrospective and 
non-randomized clinical studies. Due to very low long-
term mortality rate in low risk patients, even without 
ablation, raises serious doubts whether it can be reduced 
further and whether a study with sufficient power could 
in fact be designed to detect a meaningful difference in 
mortality. To reach a consensus whether RAI can safely 
be omitted in low risk patients with WDTC and avoiding 
these patients from possible SPM and other side effect of 
RAI, we must wait for the results of the non-inferiority 
randomized trial currently underway in United Kingdom 
(Mallick et al., 2012).
Low or High Dose of RAI for Remnant 
Ablation?
Another area of ongoing controversy is the optimal 
dose of RAI required to successfully ablate remnant 
tissue after total or near total thyroidectomy with a single 
administration in low risk group. This can be achieved 
by either dosimetry method introduced by Benua et al. 
(1962) or by fixed empiric activity of RAI. According to 
Maxon et al. (1983), about 30,000 rad (300Gy) radiation 
dose to thyroid bed was required for successful ablation 
and Bal and Padhy (1996) found 50mCi (1850MBq) of 
RAI to deliver this required dose to thyroid bed after 
total thyroidectomy. However, due to cumbersomeness 
of dosimetry method, majority of treating physicians 
have adopted fixed empiric activity of RAI (30-200mCi 
or 1110-7400MBq) with no consensus about adequate 
ablative dose in low risk patients. Some are proponents of 
low dose like 30-50mCi (1110-1850MBq) of RAI (Leung 
et al., 1992; Bal et al., 1996) while others believe that a 
higher dose like 100-150mCi (3700-5550MBq) is more 
effective in ablating the remnant thyroid tissue (Doi et al., 
2000; Doi and Woodhouse 2000; Sawka et al., 2004). The 
basic reason of this disagreement is due to lack of reliable 
evidence from retrospective and non-randomized nature 
of most of studies, different selection criteria, variation 
in adequacy of surgery and different criteria used for 
successful remnant ablation. Advantages of low dose of 
RAI are shorter stay in hospital, fewer side effects, lower 
risk of SPM and reduced cost of treatment (Mallick et 
al., 2012). While proponents of high RAI dose give 
more weightage to benefits of complete ablation rather 
than insignificant side effects of higher doses of RAI. A 
historical large clinical trial was conducted by Bal et al. 
(2004) from India including 509 patients with WDTC 
who were divided into 8 treatment groups [received RAI 
from 15-50mCi (555-1850MBq)] to find out the optimal 
ablative dose. They concluded that a RAI of at least 25mCi 
(925MBq) had better chance of remnant ablation and any 
activity between 25-50mCi (925-1850MBq) of RAI was 
found adequate for remnant ablation (Bal et al., 2004). 
However, this study was criticized due to inadequate 
surgery in 28% patients resulting in higher neck uptake 
of RAI, variable time between ablation and surgery and 
low number of patients in groups who received least RAI. 
A systematic review of randomized and observational 
studies (predominantly with small sample sizes) was 
inconclusive as to whether low dose RAI (30mCi or 
1110MBq) was associated with rates of ablation success 
that were similar to or lower than rates with high-dose 
radioiodine (100mCi or 3700MBq) (Hackshaw et al., 
2007). However, a recently published metaanalysis of 
nine randomized studies including 2569 patients revealed 
30mCi (1110MBq) RAI ablative dose as effective as 
100mCi (3700MBq) with similar quality of life, less 
common adverse effects, and a shorter hospital stay 
(Cheng et al., 2013). But a metaanalysis including 13 
studies comparing outcomes in 967 patients (518 treated 
with low dose and 449 treated with high dose RAI) 
revealed better efficiency of high RAI dose than low dose 
in achieving successful ablation (Doi and Woodhouse, 
2000). Due to these variable results, there has been a lack 
of consensus among various thyroid organizations on 
the optimum RAI dose for remnant ablation in low risk 
group. The British Thyroid Association’s 2007 guidelines 
recommend the use of high dose (BTA Guidelines, 2007). 
National Comprehensive Cancer Network (NCCN 
guidelines. 2010), the American Thyroid Association (ATA 
guidelines, 2009) and European Thyroid Cancer Task 
Force consensus report (ETCTF consensus report, 2006) 
advise that clinicians can choose between the low dose 
and the high dose due to lack of reliable evidence from 
large randomized studies (Mallick et al., 2012). In 2008 
a prospective randomized open label trial from Finland 
was published which compared the efficacy of low [30 
mCi (1110 MBq) of I-131] and high dose [100 mCi (3700 
MBq) of I-131] in 160 patients with total or near total 
thyroidectomy (Maenpaa et al., 2008). The results of this 
trial showed that low ablative dose has similar efficacy to 
higher dose with lesser side effects (Maenpaa et al., 2008). 
Meltem Caglara et al. (2012) from Turkey conducted a 
prospective randomized trial upon 108 low risk patients 
and found equal successful ablation rates in patients 
treated with 21.6mCi (800MBq) and 100mCi (3700MBq) 
of RAI. Schlumberger et al. (2012) published multicenter 
randomized French trial including 752 low risk patients 
(pT1 or pT2 with or without nodal metastasis but no distant 
metastasis) who had total thyroidectomy for WDTC and 
given 30mCi (1110MBq) and 100mCi (3700MBq) of RAI. 
They found similar successful ablation rates in low and 
high dose groups and similar ablation efficacy in patients 
pretreated with rhTSH or thyroid hormone withdrawal 
(Schlumberger et al., 2012). Mallick et al. (2012) 
published findings of a similar and carefully designed 
randomized, non-inferiority multicenter British trial (HiLo 
Trial) including 421 patients with WDTC (T1-3, N0/
N1/Nx, Mo). They also inferred that 30mCi (1110MBq) 
radioiodine was as effective as 100mCi (3700MBq) dose 
with a lower rate of adverse events. The plausible reason 
of cascade of these recent studies favoring low ablative 
dose of RAI in patients with WDTC is adequacy of total 
or near thyroidectomy leaving little tissue over thyroid 
bed translated into low baseline serum Tg levels. This 
notion is supported by an ancillary observation in a study 
which revealed unsuccessful ablation in all 18 patients 
with serum Tg≥20ng/mL at baseline regardless of dose of 
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RAI administered, whereas it was successful in 83 (61%) 
of patients who had a serum Tg concentration <20ng/mL 
(Maenpaa et al., 2008). Similarly the baseline stimulated 
serum Tg level with negative antithyroid antibodies was 
<2ng/ml in 111/438 patients in HiLo Trial (Mallick et al., 
2012) and ≤1ng/ml in 315/652 patients of French Trial 
(Schlumberger et al., 2012). This important observation 
from these randomized trials draws our attention towards 
“completeness” of total or near total thyroidectomy and 
importance of high volume thyroid surgeons. Therefore, 
a good surgery helps nuclear physicians in treating these 
low risk patients using low dose RAI for remnant ablation 
which is cost effective, requires shorter hospital stay [or 
no stay in countries where 30mCi (1110 MBq) can be 
given on out-patient basis] with lower short and long term 
adverse effects. Furthermore, inclusion of these patients 
with adequate thyroid surgery in ongoing randomize trials 
would certainly help to ascertain the role of adjuvant RAI 
in patients with low risk WDTC.
We conclude that in low risk WDTC, an adequately 
performed total or near thyroidectomy ensures use of either 
low or no adjuvant RAI and minimizing the probabilities 
of second primary malignancy and adverse effects. The 
evolving results of ongoing randomized trials upon low 
risk patients may shift the burden from nuclear physicians 
to high volume thyroid surgeons and endocrinologists.
Acknowledgements 
It is with great sadness that we must inform the 
scientific community of the passing of Prof Ajit Kumar 
Padhy in August, 2013. He will be sorely missed.
References
Bal CS, Kumar A, Pant GS (2004). Radioiodine dose for remnant 
ablation in differentiated thyroid carcinoma: a randomized 
clinical trial in 509 patients. J Clin Endocrinol Metab, 89, 
1666-73.
Bal CS, Padhy AK, Jana S, et al (1996). Prospective randomized 
clinical trial to evaluate the optimal dose of 131I for remnant 
ablation in patients with differentiated thyroid carcinoma. 
Cancer, 77, 2574-80. 
Benua RS, Cicle NR, Sonenberg et al (1962). The relation of 
radioiodine dosimetry to results and complications in the 
treatment of metastatic thyroid cancer. Am J Roentgenol, 
87, 171-82. 
Brierley J, Tsang R, Panzarella T, et al (2005). Prognostic 
factors and the effect of treatment with radioactive iodine 
and external beam radiation on patients with differentiated 
thyroid cancer seen at a single institution over 40 years. Clin 
Endocrinol, 63, 418-27. 
Caglara M, Bozkurta FM, Akcaa CK, et al (2012). Comparison of 
800 and 3700MBq iodine-131 for the postoperative ablation 
of thyroid remnant in patients with low-risk differentiated 
thyroid cancer. Nuclear Med Communications, 33 268-74. 
Carballo M, Quiros RM (2012). To treat or not to treat: the role 
of adjuvant radioiodine therapy in thyroid cancer patients. 
J Oncol, 2012, 707156.
Cheng W, Ma C, Fu H, et al (2013). Low- or high-dose 
radioiodine remnant ablation for differentiated thyroid 
carcinoma: a meta-analysis. J Clin Endocrinol Metab, 98, 
1353-60.
Cooper DS, Doherty GM, Haugen BR (2009). Revised American 
thyroid association management guidelines for patients with 
thyroid nodules and differentiated thyroid cancer. Thyroid, 
19, 1167-214.
Davies L, Welch HG (2002). Increasing incidence of thyroid 
cancer in the United States, 1973-2002. JAMA, 295, 2164-67.
Doi SAR, Woodhouse NJ (2000). Ablation of the thyroid 
remnant and 131I dose in differentiated thyroid cancer. Clin 
Endocrinol, 52, 763-73. 
Doi SAR, Woodhouse NJ, Thalib L, et al (2007). Ablation of 
the thyroid remnant and I-131 dose in differentiated thyroid 
cancer: a meta-analysis revisited. Clinical Med & Res, 5, 
87-90.
Edwards BK, Howe HL, Ries LA, et al (2002). Annual report 
to the nation on the status of cancer, 1973-1999, featuring 
implications of age and aging on US cancer burden. Cancer, 
94, 2766-92. 
Elisei R, Molinaro E, Agate L, et al (2010). Are the clinical and 
pathological features of differentiated thyroid carcinoma 
really changed over the last 35 years? Study on 4187 patients 
from a single Italian institution to answer this question. J 
Clin Endocrinol Metab, 95, 1516-27.
Grebe SKG, Hay ID (1997). Follicular cell-derived thyroid 
carcinomas. In: Arnold A, ed, Endocrine neoplasms. Kluwer 
Academic Publishers, 91-140. 
Hackshaw A, Harmer C, Mallick U, et al (2007). 131I activity 
for remnant ablation in patients with differentiated thyroid 
cancer: a systematic review. J Clin Endocrinol Metab, 92, 
28-38.
Hay ID, Thompson GB, Grant CS, et al (2002). Papillary thyroid 
carcinoma managed at the Mayo Clinic during six decades 
(1940-1999): temporal trends in initial therapy and long-
term outcome in 2444 consecutively treated patients. World 
J Surg, 26, 879-85. 
Haymart MR, Banerjee M, Stewart AK, et al (2011). Use of 
radioactive iodine for thyroid cancer. JAMA, 306, 721-28. 
Iyer NG, Morris LG, Tuttle RM, et al (2011). Rising incidence 
of second cancers in patients with low-risk (T1N0) thyroid 
cancer who receive radioactive iodine therapy. Cancer, 
117, 4439-46.
Jonklaas J, Cooper DS, Ain BK, et al (2010). Radioiodine 
therapy in patients with stage 1 differentiated thyroid cancer. 
Thyroid, 20, 1423-6.
Leung SF, Law MW, Ho SK (1992). Efficacy of low-dose 
iodine-131 ablation of post-operative thyroid remnants: a 
study of 69 cases. Bri J Radiol, 65, 905-9.
Maenpaa HO, Heikkonen J, Vaalavirta L, et al (2008). Low 
vs. high radioiodine activity to ablate the thyroid after 
thyroidectomy for cancer: a randomized study. PLoS ONE, 
3, 1885
Mallick U, Harmer C, Hackshaw A, et al (2012). Iodine or not 
(IoN) for low-risk differentiated thyroid cancer; the next UK 
national cancer research network randomized trial following 
HiLo. Clin Oncol, 24, 159-61. 
Mallick U, Harmer C, Yap B, et al (2012). Ablation with low-
dose radioiodine and thyrotropin alfa in thyroid cancer. N 
Engl J Med, 366, 1674-85.
Maxon HR, Thomas SR, Hertzberg VS, et al (1983). Relation 
between effective radiation dose and outcome of radioiodine 
therapy for thyroid cancer. N Engl J Med, 309, 937-41.
Mazzaferri EL, Kloos RT (2001). Current approaches to primary 
therapy for papillary and follicular thyroid cancer. J Clin 
Endocrinol Metab, 96, 1447-63.
Mazzaferri EL, Young RL (1981). Papillary thyroid carcinoma: 
a 10 year follow-up report of the impact of therapy in 576 
patients. Am J Med, 70, 511-8.
Pacini F, Cetani F, Miccoli P, et al (1994). Outcome of 309 
Asian Pacific Journal of Cancer Prevention, Vol 14, 2013 6213
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11.6209
Controversies about Radioactive Iodine-131 Remnant Ablation in Low Risk Thyroid Cancers: Are We Near A Consensus?
patients with metastatic differentiated thyroid carcinoma 
treated with radioiodine. World J Surg, 18, 600-4.
Robbins RJ, Schlumberger MJ (2005). The evolving role of 
131I for the treatment of differentiated thyroid carcinoma. 
J Nucl Med, 46, 28-37.
 Rubino C, de Vathaire F, Dottorini ME, et al (2003). Second 
primary malignancies in thyroid cancer patients. Br J 
Cancer, 89, 1638-44.
Sandeep TC, Strachan MW, Reynolds RM, et al (2006). Second 
primary cancers in thyroid cancer patients: a multinational 
record linkage study. J Clin Endocrinol Metab, 91, 1819-25.
Sawka AM, Thephamongkhol K, Brouwers M, et al (2004). 
Clinical review 170: A systematic review and metaanalysis 
of the effectiveness of radioactive iodine remnant ablation 
for well-differentiated thyroid cancer. J Clin Endocrinol 
Metab, 89, 3668-76.
Schlumberger M, Catargi B, Borget I, et al (2012). Strategies of 
radioiodine ablation in patients with low-risk thyroid cancer. 
N Engl J Med, 366, 1663-73.
Schvartz C, Bonnetain F, Dabakuyo, et al (2012). Impact 
on overall survival of radioactive iodine in low-risk 
differentiated thyroid cancer patients. J Clin Endocrinol 
Metab, 97, 1526-35.
Seidlin S, Oshry E, Yallow AA (1948). Spontaneous and 
experimentally induced uptake of radioactive iodine in 
metastases from thyroid carcinoma. J Clin Endocrinol 
Metab, 8, 423- 25.
Shen DH, Kloos RT, Mazzaferri EL, Jhian SM (2001). Sodium 
iodide symporter in health and disease. Thyroid, 11, 415-25.
Simpson WJ, Panzarella T, Carruthers JS, et al (1998). Papillary 
and follicular thyroid cancer: impact of treatment in 1578 
patients. Int J Radiat Oncol Biol Phys, 14, 1063-75.
Solomon BL, Wartofsky L, Burman KD (1996). Current trends 
in the management of well differentiated papillary thyroid 
carcinoma. J Clin Endocrinol Metab, 81, 333-9.
Vaisman F, Shaha A, Fish S, et al (2001). Initial therapy with 
either thyroid lobectomy or total thyroidectomy without 
radioactive iodine remnant ablation is associated with 
very low rates of structural disease recurrence in properly 
selected patients with differentiated thyroid cancer. Clinical 
Endocrinology, 75, 112-9.
Wartofsky L, Sherman SI, Gopal J, et al (1998). Therapeutic 
controversy: the use of radioactive iodine in patients with 
papillary and follicular thyroid cancer. J Clin Endocrinol 
Metab, 83, 4195-203. 
Yamashita H, Noguchi S, Murakami N, et al (1997). Extracapsular 
invasion of lymph node metastasis is an indicator of distant 
metastasis and poor prognosis in patients with thyroid 
papillary carcinoma. Cancer, 80, 2268-72.
